1-800-710-4674

Blog Post

Return to News

Feature Story

 
CLL treatment

OHC Clinical Research Experts Study New Treatment That May Help CLL Patients

Miguel Islas-Ohlmayer, MD, OHC oncologist, hematologist, transplant specialist and Principal Investigator, Blogs, 0 comments
August 5, 2019

 

The cancer experts at OHC are evaluating a new treatment that may result in a longer remission for patients diagnosed with chronic lymphocytic leukemia (CLL).

CLL can rarely be cured. Most people diagnosed with CLL will be treated on and off for years. Learning to live with a chronic disease can be difficult and very stressful.

OHC researchers are participating in a clinical trial that is evaluating a treatment that could extend the survival rate by surgically removing as much of a tumor as possible (debulking) followed by treatment with the immunotherapy drugs, venetoclax and obinutuzumab.

In some cases, surgeons would remove as much of the tumor as possible, then we would follow with chemotherapy or radiation. The debulking would increase the chance that chemotherapy or radiation would kill all the tumor cells. OHC is participating in a clinical trial that is looking at a new treatment that would begin with debulking but now followed with immunotherapy drugs.

The new treatment uses immunotherapy drugs instead of chemotherapy because they can help the body’s own immune system recognize and attack the cancer cells and preserve healthy cells.

If successful, it could offer patients a longer survival without their cancer continuing to grow. And it could allow patients to return to their favorites activities since immunotherapy drugs often cause fewer side effects than chemotherapy.

At OHC, our renown clinical research experts are bringing the latest treatments to our community to help patients win their battle with cancer. If you or someone you know has been diagnosed with CLL or another type of cancer, contact OHC to learn more about treatment options, or for a second opinion, at ohcare.com or call 1-800-710-4674.

 
 

Leave a Reply

Your email address will not be published. Required fields are marked *